

St Thomas' Advanced Revascularisation Symposium



INTRODUCTION

In its 5th anniversary, **STARS 2019** offers a unique opportunity to engage with a selected national and international faculty discussing and debating critical issues in vascular and endovascular surgery. **STARS 2019** will continue to be an informal and interactive forum to exchange expertise and knowledge between attendees and key opinion leaders. Taking place in the newly renovated County Hall in central London, **STARS 2019** also offers an excellent opportunity for networking and exposure to the newest technologies and recent developments in the field of complex vascular interventions.

STARS Directors:

Mr. Hany Zayed

Consultant Vascular Surgeon Guy's and St Thomas' NHS Foundation Trust

Dr. Tarun Sabharwal

Consultant Interventional Radiologist Guy's and St. Thomas' NHS Foundation Trust

International faculty:

Dr Theodosios Bisdas St. Franziskus Hospital, Muenster, Germany

Dr Rick de Graaf Chief of Radiology, Interventional Radiology and Nuclear Medicine;

Coordinating Director of Vascular Medicine at the Clinical Centre of

Friedrichshafen, Germany

Dr Lanfroi Graziani Head of Interventional Cardiology, Istituto Clinico Citta Di Brescia Hospital,

Brescia, Italy

Dr Peter Goverde Consultant Vascular Surgeon, Stuivenberg Hospital, Antwerp, Belgium

Dr Kostas KatsanosGreeceMr Wael TawfikDublin

UK faculty:

Mr Mohamed Abdelhamid St George's Hospital

Mr Said AbisiGuy's & St Thomas' HospitalMr Stephen BlackGuy's & St Thomas' Hospital

Dr Amman BoliaLeicesterProfessor Andrew BradburyBirmingham

Dr Karen BreenLondon Bridge HospitalMr Patrick ChongFrimley Park Hospital

Dr Trevor Cleveland Sheffield

Mr Rob DaviesLeicester Royal InfirmaryDr Athanasios DiamantopoulosGuy's & St Thomas' HospitalMr Tommaso DonatiGuy's & St Thomas' HospitalMr Rick GibbsImperial College LondonDr Mo HamadyImperial College LondonMr Keith JonesFrimley Park HospitalDr Narayan KarunanithyGuy's & St Thomas' Hospital

Mr Paul Moxey St George's Hospital

Mr Hosam Nasr Birmingham

Mr Ashish PatelGuy's & St Thomas' HospitalMr Sanjay PatelGuy's & St Thomas' HospitalDr Muhammad RamzanFreeman Hospital, NewcastleDr Tarun SabharwalGuy's & St Thomas' HospitalMr Prakash SahaGuy's & St Thomas' HospitalMr Morad SallamGuy's & St Thomas' Hospital

Mr Athanasios Saratzis Leicester

Miss Kaji Sritharan Royal Liverpool University Hospital

Dr Narayan Thulasidan Guy's & St Thomas' Hospital

Mr Chris Twine Bristol

Mr Hany Zayed Guy's & St Thomas' Hospital

PROGRAMME

08.45-09.25	Updates Session:				
	Moderators: Dr Ta	arun Sabharwal and Miss Kaji Sritharan	T		
	08.45-08.55	Updates on BASIL-2 and BASIL-3	Prof Andrew Bradbury		
	08.55-09.05	Updates on the endovascular management of acute limb ischaemia	Dr Mo Hamady		
	09.05-09.15	Stroke therapy - the clinical benefits, and the problems of service delivery	Dr Trevor Cleveland		
	09.15-09.25	Revascularisation of subclavian arteries: When and how to do	Mr Said Abisi		
09.30-10.10	Aorto-iliac segment				
	Moderators: Mr Hany Zayed and Dr Mo Hamady				
	09.30-09.40	CERAB and Ch-CERAB: My approach and the importance of patient selection	Dr Peter Goverde		
	09.40-09.50	Alternative endovascular techniques for aorto-iliac reconstruction	Mr Wael Tawfik		
	Debate: Aorto-bi-iliac occlusions (TASC II C&D)				
	09.50-10.00	Surgical reconstruction is the best treatment strategy	Mr Rick Gibbs		
	10.00-10.10	Endovascular or hybrid reconstruction is the best treatment strategy	Dr Theodosios Bisdas		
10.15-10.45	My most challenging case as a first year consultant				
	Moderators: Dr Tarun Sabharwal and Mr Morad Sallam				
	10.15-10.25	Mr Prakash Saha			
	10.25-10.35	Mr Paul Moxey			
	10.35-10.45	Mr Mohamed Abdelhamid			
10.45-10.55	Cold Spanner consists COOK MEDICAL				
10.45-10.55	Gold Sponsor session: COOK MEDICAL Moderator: Dr Tarun Sabharwal				
	Paclitaxel meta-analysis-how has this impacted my clinical practice Mr Paul Moxey				
		3			
10.55-11.25	COFFEE				
11.25-12.55	Femoro-popliteal segment				
	Moderators: Mr Hany Zayed and Dr Trevor Cleveland				
	Debate: Common femoral artery is a "surgery-only territory"				
	Debate: Common	n femoral artery is a "surgery-only territory"			
	11.25-11.35	For:	Mr Chris Twine		
			Mr Chris Twine Mr Rob Davies		
	11.25-11.35	For:			
	11.25-11.35 11.35-11.45	For: Against:	Mr Rob Davies Dr Theodosios Bisdas		
	11.25-11.35 11.35-11.45 11.45-11.55	For: Against: Drug-eluting stents in the SFA: When to use them and which one to use Supera vs drug-eluting stents in the femoro-popliteal segment: 2 years	Mr Rob Davies Dr Theodosios Bisdas		
	11.25-11.35 11.35-11.45 11.45-11.55 11.55-12.05	For: Against: Drug-eluting stents in the SFA: When to use them and which one to use Supera vs drug-eluting stents in the femoro-popliteal segment: 2 years outcomes in two matched cohorts	Mr Rob Davies Dr Theodosios Bisdas Mr Athanasios Saratzi		
	11.25-11.35 11.35-11.45 11.45-11.55 11.55-12.05 12.05-12.15 12.15-12.25	For: Against: Drug-eluting stents in the SFA: When to use them and which one to use Supera vs drug-eluting stents in the femoro-popliteal segment: 2 years outcomes in two matched cohorts Subintimal angioplasty: My approach from decades of experience Popliteal artery aneurysm: Open vs Endo, and the importance of patient	Mr Rob Davies Dr Theodosios Bisdas Mr Athanasios Saratzi Dr Amman Bolia		
	11.25-11.35 11.35-11.45 11.45-11.55 11.55-12.05 12.05-12.15 12.15-12.25	For: Against: Drug-eluting stents in the SFA: When to use them and which one to use Supera vs drug-eluting stents in the femoro-popliteal segment: 2 years outcomes in two matched cohorts Subintimal angioplasty: My approach from decades of experience Popliteal artery aneurysm: Open vs Endo, and the importance of patient selection	Mr Rob Davies Dr Theodosios Bisdas Mr Athanasios Saratzi Dr Amman Bolia		
	11.25-11.35 11.35-11.45 11.45-11.55 11.55-12.05 12.05-12.15 12.15-12.25 Debate: Paclitaxe	For: Against: Drug-eluting stents in the SFA: When to use them and which one to use Supera vs drug-eluting stents in the femoro-popliteal segment: 2 years outcomes in two matched cohorts Subintimal angioplasty: My approach from decades of experience Popliteal artery aneurysm: Open vs Endo, and the importance of patient selection	Mr Rob Davies Dr Theodosios Bisdas Mr Athanasios Saratzi Dr Amman Bolia Mr Tommaso Donati		
	11.25-11.35 11.35-11.45 11.45-11.55 11.55-12.05 12.05-12.15 12.15-12.25 Debate: Paclitaxe 12.25-12.35	For: Against: Drug-eluting stents in the SFA: When to use them and which one to use Supera vs drug-eluting stents in the femoro-popliteal segment: 2 years outcomes in two matched cohorts Subintimal angioplasty: My approach from decades of experience Popliteal artery aneurysm: Open vs Endo, and the importance of patient selection Pl-eluting devices are associated with medium and long-term mortality: For:	Mr Rob Davies Dr Theodosios Bisdas Mr Athanasios Saratzi Dr Amman Bolia Mr Tommaso Donati Dr Kostas Katsanos Dr Trevor Cleveland		
12.55-13.15	11.25-11.35 11.35-11.45 11.45-11.55 11.55-12.05 12.05-12.15 12.15-12.25 Debate: Paclitaxe 12.25-12.35 12.35-12.45 12.45-12.55	For: Against: Drug-eluting stents in the SFA: When to use them and which one to use Supera vs drug-eluting stents in the femoro-popliteal segment: 2 years outcomes in two matched cohorts Subintimal angioplasty: My approach from decades of experience Popliteal artery aneurysm: Open vs Endo, and the importance of patient selection el-eluting devices are associated with medium and long-term mortality: For: Against: Association between Paclitaxel and mortality:	Mr Rob Davies Dr Theodosios Bisdas Mr Athanasios Saratzi Dr Amman Bolia Mr Tommaso Donati Dr Kostas Katsanos Dr Trevor Cleveland		
12.55-13.15	11.25-11.35 11.35-11.45 11.45-11.55 11.55-12.05 12.05-12.15 12.15-12.25 Debate: Paclitaxe 12.25-12.35 12.35-12.45 12.45-12.55	For: Against: Drug-eluting stents in the SFA: When to use them and which one to use Supera vs drug-eluting stents in the femoro-popliteal segment: 2 years outcomes in two matched cohorts Subintimal angioplasty: My approach from decades of experience Popliteal artery aneurysm: Open vs Endo, and the importance of patient selection el-eluting devices are associated with medium and long-term mortality: For: Against: Association between Paclitaxel and mortality: Analysis of 1071 real-life patients in two matched cohorts	Mr Rob Davies Dr Theodosios Bisdas Mr Athanasios Saratzi Dr Amman Bolia Mr Tommaso Donati Dr Kostas Katsanos		

13.15-14.15	LUNCH					
14.15-14.45	My most challenging case as a first year consultant					
	Moderators: Mr Hany Zayed and Mr Patrick Chong					
	14.15-14.25	Mr Ashish Patel				
	14.25-14.35	Mr Hosam Nasr				
	14.35-14.45	Dr Muhammad Ramzan				
14.45-15.25	Infra-popliteal segment					
	Moderators: Dr Lanfroi Graziani and Dr Kostas Katsanos					
	Debate:					
	14.45-14.55	Distal and ultra-distal bypasses are still the gold standard for tibial occlusions in CLI	Mr Sanjay Patel			
	14.55-15.05	Extreme endovascular tibial revascularisation is now the gold standard for tibial occlusions in CLI	Dr Athanasios Diamantopoulos			
	15.05-15.15	Extreme tibial revascularisation: Lessons learned from decades of experience	Dr Lanfroi Graziani			
	15.15-15.25	Endovascular approaches to complex popliteal trifurcation disease	Dr Kostas Katsanos			
		Platinum Sponsor session: BOSTON SCIENTIFIC				
15.25-15.45	Platinum Spons	sor session: BOSTON SCIENTIFIC				
5.25-15.45	Platinum Spons Moderator: Dr Ta					
15.25-15.45	Moderator: Dr Ta		Mr Stephen Black			
15.25-15.45	Moderator: Dr Ta	arun Sabharwal	Mr Stephen Black			
	Moderator: Dr Ta	arun Sabharwal	Mr Stephen Black			
15.45-16.20	Moderator: Dr Ta	arun Sabharwal r Venous Intervention – efficacy, cost, and the future	Mr Stephen Black			
15.45-16.20	Moderator: Dr Ta The evidence for TEA Venous Session	arun Sabharwal r Venous Intervention – efficacy, cost, and the future	Mr Stephen Black			
15.45-16.20	Moderator: Dr Ta The evidence for TEA Venous Session	r Venous Intervention – efficacy, cost, and the future	Mr Stephen Black Dr Rick de Graaf			
l5.45 -16.2 0	Moderator: Dr Ta The evidence for TEA Venous Session Moderators: Mr S	r Venous Intervention – efficacy, cost, and the future Steve Black, Dr Rick de Graaf and Mr Prakash Saha Updates on the management of DVT: Results of ATTRACT and CAVA				
15.45-16.20	Moderator: Dr Ta The evidence for TEA Venous Session Moderators: Mr S 16.20-16.30	r Venous Intervention – efficacy, cost, and the future Steve Black, Dr Rick de Graaf and Mr Prakash Saha Updates on the management of DVT: Results of ATTRACT and CAVA trials	Dr Rick de Graaf			
15.25-15.45 15.45-16.20 16.20-17.10	Moderator: Dr Ta The evidence for TEA Venous Session Moderators: Mr S 16.20-16.30 16.30-16.40	r Venous Intervention – efficacy, cost, and the future Steve Black, Dr Rick de Graaf and Mr Prakash Saha Updates on the management of DVT: Results of ATTRACT and CAVA trials Post-partum DVT: How to manage and Is there a role of intervention?	Dr Rick de Graaf Dr Karen Breen			
15.45-16.20	Moderator: Dr Ta The evidence for TEA Venous Session Moderators: Mr S 16.20-16.30 16.30-16.40 16.40-16.50	r Venous Intervention – efficacy, cost, and the future Steve Black, Dr Rick de Graaf and Mr Prakash Saha Updates on the management of DVT: Results of ATTRACT and CAVA trials Post-partum DVT: How to manage and Is there a role of intervention? Upper limb DVT: Role of endovascular treatment	Dr Rick de Graaf Dr Karen Breen Mr Prakash Saha Dr Narayanan			
15.45-16.20 16.20-17.10	Moderator: Dr Ta The evidence for TEA Venous Session Moderators: Mr 9 16.20-16.30 16.30-16.40 16.40-16.50 16.50-17.00 17.00-17.10	r Venous Intervention – efficacy, cost, and the future Steve Black, Dr Rick de Graaf and Mr Prakash Saha Updates on the management of DVT: Results of ATTRACT and CAVA trials Post-partum DVT: How to manage and Is there a role of intervention? Upper limb DVT: Role of endovascular treatment Management of SVC occlusions: Updates and new approaches Venous stenting for chronic venous ulceration: Does it work: Tips and tricks	Dr Rick de Graaf Dr Karen Breen Mr Prakash Saha Dr Narayanan Thulasidan			
15. 45-16.20 16.20-17.10	Moderator: Dr Ta The evidence for TEA Venous Session Moderators: Mr S 16.20-16.30 16.30-16.40 16.40-16.50 16.50-17.00 17.00-17.10 How I do it (rec	r Venous Intervention – efficacy, cost, and the future Steve Black, Dr Rick de Graaf and Mr Prakash Saha Updates on the management of DVT: Results of ATTRACT and CAVA trials Post-partum DVT: How to manage and Is there a role of intervention? Upper limb DVT: Role of endovascular treatment Management of SVC occlusions: Updates and new approaches Venous stenting for chronic venous ulceration: Does it work: Tips and tricks	Dr Rick de Graaf Dr Karen Breen Mr Prakash Saha Dr Narayanan Thulasidan			
15. 45-16.20 16.20-17.10	Moderator: Dr Ta The evidence for TEA Venous Session Moderators: Mr S 16.20-16.30 16.30-16.40 16.40-16.50 16.50-17.00 17.00-17.10 How I do it (rec Moderators: Dr T	r Venous Intervention – efficacy, cost, and the future Steve Black, Dr Rick de Graaf and Mr Prakash Saha Updates on the management of DVT: Results of ATTRACT and CAVA trials Post-partum DVT: How to manage and Is there a role of intervention? Upper limb DVT: Role of endovascular treatment Management of SVC occlusions: Updates and new approaches Venous stenting for chronic venous ulceration: Does it work: Tips and tricks corded cases) Farun Sabharwal and Mr Keith Jones	Dr Rick de Graaf Dr Karen Breen Mr Prakash Saha Dr Narayanan Thulasidan			
15.45-16.20	Moderator: Dr Ta The evidence for TEA Venous Session Moderators: Mr S 16.20-16.30 16.30-16.40 16.40-16.50 16.50-17.00 17.00-17.10 How I do it (rec Moderators: Dr T (8 minute talk; 4	r Venous Intervention – efficacy, cost, and the future Steve Black, Dr Rick de Graaf and Mr Prakash Saha Updates on the management of DVT: Results of ATTRACT and CAVA trials Post-partum DVT: How to manage and Is there a role of intervention? Upper limb DVT: Role of endovascular treatment Management of SVC occlusions: Updates and new approaches Venous stenting for chronic venous ulceration: Does it work: Tips and tricks corded cases) Tarun Sabharwal and Mr Keith Jones minute discussion)	Dr Rick de Graaf Dr Karen Breen Mr Prakash Saha Dr Narayanan Thulasidan			
15. 45-16.20 16.20-17.10	Moderator: Dr Ta The evidence for TEA Venous Session Moderators: Mr S 16.20-16.30 16.30-16.40 16.40-16.50 16.50-17.00 17.00-17.10 How I do it (rec Moderators: Dr T	r Venous Intervention – efficacy, cost, and the future Steve Black, Dr Rick de Graaf and Mr Prakash Saha Updates on the management of DVT: Results of ATTRACT and CAVA trials Post-partum DVT: How to manage and Is there a role of intervention? Upper limb DVT: Role of endovascular treatment Management of SVC occlusions: Updates and new approaches Venous stenting for chronic venous ulceration: Does it work: Tips and tricks corded cases) Farun Sabharwal and Mr Keith Jones	Dr Rick de Graaf Dr Karen Breen Mr Prakash Saha Dr Narayanan Thulasidan Mr Steve Black Dr Peter Goverde Dr Narayanan			
15.45-16.20 16.20-17.10	Moderator: Dr Ta The evidence for TEA Venous Session Moderators: Mr S 16.20-16.30 16.30-16.40 16.40-16.50 16.50-17.00 17.00-17.10 How I do it (rec Moderators: Dr T (8 minute talk; 4 17.10	r Venous Intervention – efficacy, cost, and the future Steve Black, Dr Rick de Graaf and Mr Prakash Saha Updates on the management of DVT: Results of ATTRACT and CAVA trials Post-partum DVT: How to manage and Is there a role of intervention? Upper limb DVT: Role of endovascular treatment Management of SVC occlusions: Updates and new approaches Venous stenting for chronic venous ulceration: Does it work: Tips and tricks corded cases) Farun Sabharwal and Mr Keith Jones minute discussion) CERAB	Dr Rick de Graaf Dr Karen Breen Mr Prakash Saha Dr Narayanan Thulasidan Mr Steve Black Dr Peter Goverde			
15.45-16.20 16.20-17.10	Moderator: Dr Ta The evidence for TEA Venous Session Moderators: Mr S 16.20-16.30 16.30-16.40 16.40-16.50 16.50-17.00 17.00-17.10 How I do it (rec Moderators: Dr T (8 minute talk; 4 17.10 17.22	r Venous Intervention – efficacy, cost, and the future Steve Black, Dr Rick de Graaf and Mr Prakash Saha Updates on the management of DVT: Results of ATTRACT and CAVA trials Post-partum DVT: How to manage and Is there a role of intervention? Upper limb DVT: Role of endovascular treatment Management of SVC occlusions: Updates and new approaches Venous stenting for chronic venous ulceration: Does it work: Tips and tricks corded cases) Farun Sabharwal and Mr Keith Jones minute discussion) CERAB Radial access	Dr Rick de Graaf Dr Karen Breen Mr Prakash Saha Dr Narayanan Thulasidan Mr Steve Black Dr Peter Goverde Dr Narayanan Thulasidan			

Dr Tarun Sabharwal

We would like to thank our sponsors for supporting this symposium

PLATINUM SPONSORS





GOLD SPONSOR



SILVER SPONSORS







BRONZE SPONSORS















Our Platinum and Gold Sponsors



Abbott Vascular, a division of Abbott, is a global leader in vascular and cardiac care with market-leading products and an industry-leading pipeline. Headquartered in Northern California, we are committed to advancing patient care by transforming the treatment of vascular disease through medical device innovations, investments in research and development, and physician training and education. We offer cuttingedge devices for coronary artery disease, peripheral vascular disease, carotid artery disease and structural heart disease. Our comprehensive product portfolio includes the Xience PRIME drug eluting stent system, self-expanding and balloon expanding bare metal stents, balloon catheters, guide wires and vessel closure devices. **www.abbott.co.uk**



Boston Scientific. We are a global leader in peripheral interventions and offer healthcare providers one of the broadest portfolios of solutions including a complete set of flow restoration technologies to treat the lower extremities, all designed to help physicians save the lives and limbs of more patients. **www.bostonscientific.com**



A global pioneer in medical breakthroughs, **Cook Medical** is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit **www.cookmedical.eu**

STRS

St Thomas' Advanced Revascularisation Symposium

This meeting has been approved as COMPLIANT by MedTech Europe Code of Ethical Business Practice.

6 hours CPD has been awarded by the RCSEd: Recognition number RCSEd02315

Notes	

